EMA/562037/2013

# European Medicines Agency decision

P/0232/2013

of 23 September 2013

on the agreement of a paediatric investigation plan and on the granting of a waiver for sapropterin dihydrochloride (Kuvan), (EMEA-001476-PIP01-13) in accordance with Regulation (EC) No 1901/2006 of the European Parliament and of the Council

**Disclaimer**

This Decision does not constitute entitlement to the rewards and incentives referred to in Title V of Regulation (EC) No 1901/2006.

**Only the English text is authentic.**

7 Westferry Circus ● Canary Wharf ● London E14 4HB ● United Kingdom
**Telephone** +44 (0)20 7418 8400 **Facsimile** +44 (0)20 7523 7040
**E-mail** info@ema.europa.eu **Website** www.ema.europa.eu

# European Medicines Agency decision

P/0232/2013

of 23 September 2013

on the agreement of a paediatric investigation plan and on the granting of a waiver for sapropterin dihydrochloride (Kuvan), (EMEA-001476-PIP01-13) in accordance with Regulation (EC) No 1901/2006 of the European Parliament and of the Council

The European Medicines Agency,

Having regard to the Treaty on the Functioning of the European Union,

Having regard to Regulation (EC) No 1901/2006 of the European Parliament and of the Council of 12 December 2006 on medicinal products for paediatric use and amending Regulation (EEC) No. 1768/92, Directive 2001/20/EC, Directive 2001/83/EC and Regulation (EC) No 726/2004[1],

Having regard to Regulation (EC) No 726/2004 of the European Parliament and of the Council of 31 March 2004 laying down Community procedures for the authorisation and supervision of medicinal products for human and veterinary use and establishing a European Medicines Agency[2],

Having regard to the application submitted by Merck KGaA on 2 May 2013 under Article 16(1) of Regulation (EC) No 1901/2006 also requesting a waiver under Article 13 of said Regulation,

Having regard to the opinion of the Paediatric Committee of the European Medicines Agency, issued on 9 August 2013, in accordance with Article 18 of Regulation (EC) No 1901/2006,

Having regard to Article 25 of Regulation (EC) No 1901/2006,

Whereas:

(1) The Paediatric Committee of the European Medicines Agency has given an opinion on the agreement of a paediatric investigation plan and on the granting of a waiver.

(2) It is therefore appropriate to adopt a decision agreeing a paediatric investigation plan.

(3) It is therefore appropriate to adopt a decision granting a waiver.

[1] OJ L 378, 27.12.2006, p.1.
[2] OJ L 136, 30.4.2004, p. 1.

Has adopted this decision:

***Article 1***

A paediatric investigation plan for sapropterin dihydrochloride (Kuvan), soluble tablet, oral use, the details of which are set out in the opinion of the Paediatric Committee of the European Medicines Agency annexed hereto, together with its appendices, is hereby agreed.

***Article 2***

A waiver for sapropterin dihydrochloride (Kuvan), soluble tablet, oral use, the details of which are set out in the opinion of the Paediatric Committee of the European Medicines Agency annexed hereto, together with its appendices, is hereby granted.

***Article 3***

This decision is addressed to Merck KGaA, Frankfurter Strasse 250, 64293 – Darmstadt, Germany.

Done at London, 23 September 2013

For the European Medicines Agency
Guido Rasi
Executive Director
(Signature on file)

EMA/PDCO/442091/2013 Corr

# Opinion of the Paediatric Committee on the agreement of a Paediatric Investigation Plan and a waiver

EMEA-001476-PIP01-13

## Scope of the application

**Active substance(s):**

Sapropterin Dihydrochloride

**Invented name:**

Kuvan

**Condition(s):**

Treatment of hyperphenylalaninemia

**Authorised indication(s):**

See Annex II

**Pharmaceutical form(s):**

Soluble tablet

**Route(s) of administration:**

Oral use

**Name/corporate name of the PIP applicant:**

Merck KGaA

**Information about the authorised medicinal product:**

See Annex II

7 Westferry Circus ● Canary Wharf ● London E14 4HB ● United Kingdom
**Telephone** +44 (0)20 7418 8400 **Facsimile** +44 (0)20 7523 7040
**E-mail** info@ema.europa.eu **Website** www.ema.europa.eu

## Basis for opinion

Pursuant to Article 16(1) of Regulation (EC) No 1901/2006 as amended, Merck KGaA submitted for agreement to the European Medicines Agency on 2 May 2013 an application for a paediatric investigation plan for the above mentioned medicinal product and a waiver under Article 13 of said Regulation.

The procedure started on 12 June 2013.

## Opinion

1. The Paediatric Committee, having assessed the proposed paediatric investigation plan in accordance with Article 17 of Regulation (EC) No 1901/2006 as amended, recommends as set out in the appended summary report:

   - to agree the paediatric investigation plan in accordance with Article 18 of said Regulation;
   - to grant a waiver for one or more subsets of the paediatric population in accordance with Article 13 of said Regulation and concluded in accordance with Article 11(1)(c) of said Regulation, on the grounds that the specific medicinal product does not represent a significant therapeutic benefit over existing treatments for paediatric patients.

   The Norwegian Paediatric Committee member agrees with the above-mentioned recommendation of the Paediatric Committee.

2. The measures and timelines of the agreed paediatric investigation plan and the subset(s) of the paediatric population and condition(s) covered by the waiver are set out in the Annex I.

This opinion is forwarded to the applicant and the Executive Director of the European Medicines Agency, together with its annexes and appendix.

London, 9 August 2013

On behalf of the Paediatric Committee
Dr Daniel Brasseur, Chairman
(Signature on file)

# Annex I

# The subset(s) of the paediatric population and condition(s) covered by the waiver and the measures and timelines of the agreed Paediatric Investigation Plan

# 1. Waiver

## *1.1. Condition: treatment of hyperphenylalaninemia*

The waiver applies to:

- The paediatric population from four years to less than 18 years;
- for soluble tablet, oral use;
- on the grounds that the specific medicinal product does not represent a significant therapeutic benefit as the needs are already covered.

# 2. Paediatric Investigation Plan

## *2.1. Condition: treatment of hyperphenylalaninemia*

### 2.1.1. Indication(s) targeted by the PIP

Treatment of phenylketonuria (PKU).

### 2.1.2. Subset(s) of the paediatric population concerned by the paediatric development

From birth to less than 4 years of age.

### 2.1.3. Pharmaceutical form(s)

Soluble tablet

### 2.1.4. Measures

| Area | Number of measures | Description |
|---|---|---|
| Quality | 0 | Not applicable. |
| Non-clinical | 0 | Not applicable. |
| Clinical | 1 | Measure 1: Open-label, randomised, multi-centre, concurrent controlled trial to evaluate, pharmacokinetics, safety and efficacy of Sapropterin Dihydrochloride as add-on to a Phenylalanine (Phe)-restricted diet compared to a Phenylalanine (Phe)-restricted diet alone, in children from birth to less than 4 years with phenylketonuria (PKU). |

## 3. Follow-up, completion and deferral of PIP

| | |
|---|---|
| Concerns on potential long term safety and efficacy issues in relation to paediatric use: | No |
| Date of completion of the paediatric investigation plan: | By January 2014 |
| Deferral for one or more measures contained in the paediatric investigation plan: | No |

# Annex II

# Information about the authorised medicinal product

## Condition(s) and authorised indication(s):

1. Treatment of hyperphenylalaninemia

   Authorised indication(s):

   - Kuvan is indicated for the treatment of hyperphenylalaninaemia in adult and paediatric patients of 4 years of age and over with phenylketonuria who have been shown to be responsive to such treatment.
   - Kuvan is also indicated for the treatment of hyperphenylalaninaemia in adult and paediatric patients with BH4 deficiency, who have been shown to be responsive to such treatment.

## Authorised pharmaceutical form(s):

Soluble tablet

## Authorised route(s) of administration:

Oral use